Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Prostatic Neoplasms 2Tongue Neoplasms 1Thymoma 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma, Endometrial Stromal 1Sarcoma 1Rhabdomyosarcoma 1Rectal Neoplasms 1Pleural Effusion, Malignant 1Pancreatic Neoplasms 1Melanoma 1Liposarcoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Fibrosarcoma 1Esophageal Neoplasms 1Dermatofibrosarcoma 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

Sunitinib 2Cyclophosphamide 2Celecoxib 2saracatinib 1fludarabine 1entinostat 1belinostat 1avelumab 1alovudine 1MK 2206 1Lapatinib 1FANG vaccine 1Erlotinib Hydrochloride 1AZD 6244 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Thymoma × saracatinib × Clear all
NCT00718809 2015-06-10

Saracatinib in Treating Patients With Relapsed or Refractory Thymoma or Thymic Cancer

National Cancer Institute (NCI)

Phase 2 Terminated
21 enrolled 13 charts
Thoracic

Thymoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡